Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: A retrospective study of three cases from a single centre and literature review
Clinical and Experimental Rheumatology, Volume 32, No. 6, Year 2014
Notification
URL copied to clipboard!
Description
Objective The aim of this paper is to assess the clinical response to golimumab (GLM) in patients with non-infectious uveitis from a single centre that had previously been treated with other anti-TNF-α drugs. Methods A retrospective chart review was carried out of patients with immune-mediated uveitis refractory to standard synthetic immunosuppressive drugs who were treated with GLM at Hospital Universitario Marqués de Valdecilla, Santander (Spain). Patients were included in this study if they had previously been treated with other anti-TNF-α drugs. A literature review of patients with immune-mediated uveitis undergoing GLM therapy was conducted. Results Three patients (2 men and 1 woman) were included in this study. Two of them were refractory to other anti-TNF-α drugs. The median age of patients was 26 years (range 20-42). Uveitis was bilateral in two patients. The underlying diseases were uveitis associated with HLA-B27 and psoriasis in one case and sarcoidosis in the other two cases. Improvement of the main ocular parameters following GLM therapy was achieved in all cases. After a median follow-up of 3 (range 1-9) months using GLM therapy, none of the patients had experienced new relapses of uveitis. None of them had side effects during treatment with this drug. A literature review disclosed that our observations were in keeping with other reports that showed good response to GLM in 13 of 16 patients with immune-mediated uveitis refractory to other biologic agents. Conclusion Although the follow-up was too short in our series, GLM could be an effective and safe therapy for the management of patients with uveitis previously treated with other anti-TNF-α drugs. © Clinical and Experimental Rheumatology 2014.
Authors & Co-Authors
Calvo-Río, Vanesa
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Blanco-Alonso, Ricardo
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Beltrán-Catalán, Emma
Spain, Valencia
Hospital General Universitario de Valencia
Loricera, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Cifrián Martínez, José Manuel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Rueda-Gotor, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Vela, María Carmen
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Gay, Miguel Ángel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Statistics
Citations: 24
Authors: 8
Affiliations: 2
Identifiers
ISSN:
0392856X
Research Areas
Health System And Policy
Study Design
Cohort Study
Study Approach
Systematic review
Participants Gender
Male
Female